Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview.

Cancer science - 1 Aug 2021

Matsuo Kentaro, Taniguchi Kohei, Hamamoto Hiroki, Inomata Yosuke, Komura Kazumasa, Tanaka Tomohito, Lee Sang-Woong, Uchiyama Kazuhisa

Abstract excerpt

Delta-like canonical Notch ligand 3 (DLL3) is a member of the Delta/Serrate/Lag2 (DSL) Notch receptor ligand family and plays a crucial role in Notch signaling, which influences various cellular processes including differentiation, proliferation, survival, and apoptosis. DLL3 is expressed throughout the presomitic mesoderm and is localized to the rostral somatic compartments; mutations in DLL3 induce skeletal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Gene Expression Regulation, Neoplastic

Share to Immunoconjugates

Share to Intracellular Signaling Peptides and Proteins

Share to Molecular Targeted Therapy

Share to Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34107132
DOI: 10.1111/cas.15017
PMCID: PMC8353941

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview.PMID 34107132Read ↗

Notch signaling pathway in cancer: from mechanistic insights to targeted therapiesSemantic proximity Read ↗

Precision medicine for human cancers with Notch signaling dysregulation (Review)Semantic proximity Read ↗

Delta-Like Protein 3 Expression and Targeting in Merkel Cell CarcinomaSemantic proximity Read ↗

Prognostic value of delta‑like protein 3 combined with thyroid transcription factor‑1 in small‑cell lung cancerSemantic proximity Read ↗

Targeting netrin‐3 in small cell lung cancer and neuroblastomaSemantic proximity Read ↗

NOTCH Signaling Pathway: Occurrence, Mechanism, and NOTCH-Directed Therapy for the Management of CancerSemantic proximity Read ↗

Notch Signaling Proteins: Legitimate Targets for Cancer TherapySemantic proximity Read ↗

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentialsSemantic proximity Read ↗

Notch Signaling in Cancer: Rationale and Strategies for TargetingSemantic proximity Read ↗

LAG-3: from molecular functions to clinical applicationsSemantic proximity Read ↗

BTN3A: A Promising Immune Checkpoint for Cancer Prognosis and TreatmentSemantic proximity Read ↗

Gene of the month: lymphocyte-activation gene 3 (LAG-3)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.